The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 800
- Locations
- 1
- Primary Endpoint
- stenosis of coronary artery
Study Overview
Brief Summary
To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human
Detailed Description
Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the atherosclerotic plaque will be evaluated.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with suspected coronary heart disease
- •patients received coronary angiography
Exclusion Criteria
- •NYHA III-IV
- •malignant tumor
- •acute infection
- •thyroid dysfunction
Outcomes
Primary Outcomes
stenosis of coronary artery
Time Frame: 1 week
The stenosis of coronary artery based on the results of coronary angiography
Secondary Outcomes
- coronary artery calcium(1 week)
Investigators
Jin Geng
associate doctor
Nanjing Medical University
